ORIGINAL CHLOROQUINE PHOSPHATE TABLETS, USP 100 MG, 250 MG and 500 MG for COVID-19

Product Details

Malaria

Prophylaxis

• Indicated for prophylaxis of malaria in geographic areas where resistance to chloroquine is not present
• 500 mg (300-mg base) weekly on the same day each week; begin 1-2 weeks before travel, during travel, and for 4 weeks after leaving endemic area (CDC 2018 [link https://www.cdc.gov/malaria/travelers/drugs.html])

Treatment

• Indicated for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum
• Acute attack
  • 1 g (600-mg base) PO, THEN
  • 500 mg (300 mg-base) PO after 6-8 hr THEN
  • 500 mg (300 mg-base) PO at 24 hr and 48 hr after initial dose
  • Total dose of 2500 mg (1500 mg-base) in 3 days

Amebiasis, Extraintestinal

1 g (600 mg base) PO qDay for 2 days, THEN

500 mg (300 mg base) qDay for 14-21 days

Coronavirus Disease 2019 (COVID-19) (Off-label)

Data available as of March 24, 2020

Note: Limited data available; no drug is FDA approved to treat COVID-19

Chloroquine may be considered for use as part of an investigational protocol for patients with COVID-19

For more information, see the CDC website (link https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html)

Additional Medscape COVID-19 references are available

• Coronavirus Disease 2019 (COVID-19) (link https://emedicine.medscape.com/article/2500114-overview)
• Novel Coronavirus Resource Center (link https://www.medscape.com/resource/coronavirus)

Porphyria Cutanea Tarda (Off-label)

125-250 mg (75-150 mg base) PO twice weekly

Glioblastoma (Orphan)

Orphan designation for treatment of glioblastoma multiforme

Sponsor

• DualTpharma B.V.; Boschstraat 111-D01; 6211 A W Maastricht; Netherlands

Dosage Modifications

Hepatic impairment

• Chloroquine phosphate tablets may concentrate in the liver; use with caution in patients with hepatic disease or alcoholism or in conjunction with known hepatotoxic drugs

Dosing Considerations

Limitations of use

• Do not use for the treatment of complicated malaria (high-grade parasitemia and/or complications [eg, cerebral malaria, acute renal failure])
• Do not use for malaria prophylaxis in areas where chloroquine resistance occurs
• Concomitant use with an 8-aminoquinoline drug is necessary for treatment of hypnozoite liver stage forms of P.vivax and P.ovale